OrthoPediatrics Beats Q4 Earnings Expectations

The medical device company focused on pediatric orthopedics reported a narrower-than-expected loss per share.

Published on Feb. 27, 2026

OrthoPediatrics (NASDAQ:KIDS), a medical device company dedicated to providing orthopedic solutions for children, reported its fourth quarter financial results on Thursday. The company reported a loss per share of $0.26, beating analysts' consensus estimate of a $0.29 loss per share. OrthoPediatrics also reported revenue of $61.61 million for the quarter, topping the $61.27 million expected by analysts.

Why it matters

OrthoPediatrics' better-than-expected financial performance demonstrates the company's ability to execute despite ongoing challenges in the healthcare industry. As a specialized player in the pediatric orthopedics market, the company's results provide insight into the demand for its innovative products designed to address a wide range of conditions in children.

The details

In addition to the narrower loss, OrthoPediatrics reported a negative return on equity of 6.86% and a negative net margin of 20.06% for the quarter. The company's stock traded up $1.07, or 6%, to $17.79 on the earnings release. OrthoPediatrics has a market capitalization of $446.17 million and its shares have traded between $15.28 and $26.40 over the past 52 weeks.

  • OrthoPediatrics reported its Q4 2025 earnings results on Thursday, February 27, 2026.

The players

OrthoPediatrics

A medical device company dedicated exclusively to providing orthopedic solutions for children, founded in 2007 and headquartered in Warsaw, Indiana.

Got photos? Submit your photos here. ›

The takeaway

OrthoPediatrics' better-than-expected financial performance in Q4 2025 demonstrates the company's ability to navigate the challenges facing the healthcare industry and meet the demand for its specialized pediatric orthopedic products.